clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Wound Infection D014946 12 associated lipids
Bacteriuria D001437 7 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Periodontal Pocket D010514 9 associated lipids
Ischemia D007511 18 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Peptic Ulcer D010437 19 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Periodontitis D010518 22 associated lipids
Nasal Polyps D009298 26 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Miftahussurur M et al. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. 2016 BMC Microbiol. pmid:27809767
Losurdo G et al. Role of concomitant therapy for eradication: A technical note. 2016 World J. Gastroenterol. pmid:27784977
Zycinska K et al. Antibiotic Treatment of Hospitalized Patients with Pneumonia Complicated by Clostridium Difficile Infection. 2016 Adv. Exp. Med. Biol. pmid:27620311
Bax HI et al. Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro. 2016 Antimicrob. Agents Chemother. pmid:26883697
Hirata Y et al. Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen. 2016 Int. J. Infect. Dis. pmid:27590563
Zhou L et al. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial. 2016 Helicobacter pmid:26104022
Plate A [Not Available]. 2016 Praxis (Bern 1994) pmid:27606919
Huh CW et al. Early Attempts to Eradicate Helicobacter pylori after Endoscopic Resection of Gastric Neoplasm Significantly Improve Eradication Success Rates. 2016 PLoS ONE pmid:27588679
Watanabe M et al. Saturated fatty acids and fatty acid esters promote the polymorphic transition of clarithromycin metastable form I crystal. 2016 Int J Pharm pmid:27553780
Nagashima A et al. Clarithromycin Suppresses Chloride Channel Accessory 1 and Inhibits Interleukin-13-Induced Goblet Cell Hyperplasia in Human Bronchial Epithelial Cells. 2016 Antimicrob. Agents Chemother. pmid:27550358
Couture G et al. [Second case of serum sickness-like reaction to claritrhomycin]. 2016 Presse Med pmid:27542759
Bugli F et al. In vitro effect of clarithromycin and alginate lyase against helicobacter pylori biofilm. 2016 Biotechnol. Prog. pmid:27535356
Shichijo S et al. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice. 2016 J Dig Dis pmid:27534444
Lotfipour F et al. Study of Antimicrobial Effects of Clarithromycin Loaded PLGA Nanoparticles against Clinical Strains of Helicobacter pylori. 2016 Drug Res (Stuttg) pmid:25919643
Büchsel M et al. A case of septic arthritis caused by a Mycoplasma salivarium strain resistant towards Ciprofloxacin and Clarithromycin in a patient with chronic lymphatic leukemia. 2016 Diagn. Microbiol. Infect. Dis. pmid:27342785
Lin LC et al. Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials. 2016 World J. Gastroenterol. pmid:27340362
Abd-Elsalam S et al. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. 2016 Medicine (Baltimore) pmid:27310977
De Francesco V et al. Two-week Triple Therapy with either Standard or High-dose Esomeprazole for First-line H. pylori Eradication. 2016 J Gastrointestin Liver Dis pmid:27308644
Miyaki A et al. An assessment of the efficacy of first-line Helicobacter pylori-eradication therapy based on clarithromycin susceptibility. 2016 Minerva Gastroenterol Dietol pmid:27304198
Okano Y et al. Miliary pulmonary nodules due to Mycobacterium xenopi in a steroid-induced immunocompromised patient successfully treated with chemotherapy: a case report. 2016 BMC Pulm Med pmid:27287608
Akram FE et al. A combination of silver nanoparticles and visible blue light enhances the antibacterial efficacy of ineffective antibiotics against methicillin-resistant Staphylococcus aureus (MRSA). 2016 Ann. Clin. Microbiol. Antimicrob. pmid:27530257
Zollner-Schwetz I et al. Primary resistance of Helicobacter pylori is still low in Southern Austria. 2016 Int. J. Med. Microbiol. pmid:27134190
Georgopoulos SD et al. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area. 2016 Eur. J. Intern. Med. pmid:27134145
Kim JS et al. Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial. 2016 Gut Liver pmid:27114421
Manniello MD et al. Aerodynamic properties, solubility and in vitro antibacterial efficacy of dry powders prepared by spray drying: Clarithromycin versus its hydrochloride salt. 2016 Eur J Pharm Biopharm pmid:27106605
Fallone CA et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. 2016 Gastroenterology pmid:27102658
Bilgilier C et al. Prevalence of clarithromycin-resistant Helicobacter pylori strains in gastric mucosa-associated lymphoid tissue lymphoma patients. 2016 Ann. Hematol. pmid:27091350
Root AA et al. Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs. 2016 Br J Clin Pharmacol pmid:27090996
Kazama I et al. Clarithromycin Dose-Dependently Stabilizes Rat Peritoneal Mast Cells. 2016 Chemotherapy pmid:27088971
Huynh VA et al. [Fixed drug eruption to clarithromycin: The importance of challenge tests in diagnosis]. 2016 Ann Dermatol Venereol pmid:27080820
Seyama S et al. Clarithromycin Resistance Mechanisms of Epidemic β-Lactamase-Nonproducing Ampicillin-Resistant Haemophilus influenzae Strains in Japan. 2016 Antimicrob. Agents Chemother. pmid:26953210
Ji Z et al. The Association of Age and Antibiotic Resistance of Helicobacter Pylori: A Study in Jiaxing City, Zhejiang Province, China. 2016 Medicine (Baltimore) pmid:26937912
Murakami K et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. 2016 Gut pmid:26935876
Park JY et al. Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA. 2016 Dig. Dis. Sci. pmid:26923948
Guirao-Arrabal E et al. Clarithromycin plus linezolid as a sequential therapy for implantable-cardioverter-defibrillator infection caused by coagulase-negative staphylococci. 2016 Rev Esp Quimioter pmid:26888341
Friedman ND et al. Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort. 2016 Antimicrob. Agents Chemother. pmid:26883709
Chua CS et al. The efficacy of blueberry and grape seed extract combination on triple therapy for Helicobacter pylori eradication: a randomised controlled trial. 2016 Int J Food Sci Nutr pmid:26883189
Trac MH et al. Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. 2016 CMAJ pmid:26903359
Mukai S et al. Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines. 2016 Int. J. Oncol. pmid:26718641
Iyer G and Alexander GC Cardiovascular risks associated with clarithromycin. 2016 BMJ pmid:26769796
Wong AY et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. 2016 BMJ pmid:26768836
Hirama T et al. PCR-Based Rapid Identification System Using Bridged Nucleic Acids for Detection of Clarithromycin-Resistant Mycobacterium avium-M. intracellulare Complex Isolates. 2016 J. Clin. Microbiol. pmid:26739154
Radheshi E et al. Postmortem diagnosis of anaphylaxis in presence of decompositional changes. 2016 J Forensic Leg Med pmid:26735898
Hassan ST et al. In vitro synergistic effect of Hibiscus sabdariffa aqueous extract in combination with standard antibiotics against Helicobacter pylori clinical isolates. 2016 Pharm Biol pmid:26731378
Çağan-Appak Y et al. Clarithromycin resistance and 23S rRNA gene point mutations of Helicobacter pylori infection in children. 2016 Turk. J. Pediatr. pmid:28276208
Thung I et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. 2016 Aliment. Pharmacol. Ther. pmid:26694080
Apostolopoulos P et al. Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study. 2016 Scand. J. Gastroenterol. pmid:26435055
Hollitt A et al. Cat scratch disease of the parotid gland. 2016 Arch. Dis. Child. pmid:26403943
Oh B et al. The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial. 2016 Helicobacter pmid:26395781
Lee J et al. A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM. 2016 J. Matern. Fetal. Neonatal. Med. pmid:26373262